Grant recipients–hailing from academia, industry, and clinical practice—will receive funding to develop new devices and other aging-related innovations
Inaugural grant recipients hailing from academia, industry, and clinical practice will receive funding to develop new devices and other aging-related innovations
Two Johns Hopkins researchers race to bring a drug to market that holds promise for millions afflicted with the devastating cognitive disorder
/ Johns Hopkins Magazine
Supriya Munshaw, an expert in drug commercialization, discusses what factors went into the FDA approval of aducanumab, a drug known by the brand name Aduhelm